Trial Profile
A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs Pegcetacoplan (Primary)
- Indications Glomerulonephritis; IgA nephropathy; Kidney disorders; Lupus nephritis; Membranoproliferative glomerulonephritis
- Focus Proof of concept; Therapeutic Use
- Acronyms DISCOVERY
- Sponsors Apellis Pharmaceuticals
- 03 Apr 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 09 Oct 2020 48-week data (n=5) presented in an Apellis Pharmaceuticals Media Release.
- 09 Oct 2020 According to an Apellis Pharmaceuticals media release, 48-week data (n=5) will be presented at the American Society of Nephrology (ASN) Kidney Week